Independent reporting on medical research: what the evidence actually shows.https://thefirstcohort.com/https://thefirstcohort.com/articles/2026-06-14-a-dod-funded-fentanyl-vaccine-is-headed-to-phase-1-antibodies-don-t-stop-a-suppl/https://thefirstcohort.com/articles/2026-06-14-a-dod-funded-fentanyl-vaccine-is-headed-to-phase-1-antibodies-don-t-stop-a-suppl/A Pentagon-funded fentanyl vaccine licensed to startup ARMR Sciences will begin Phase 1 in the Netherlands in early 2026. Three decades of failed addiction vaccines, and a supply chain that runs through Chinese precursor labs, are the context the press release leaves out.Sun, 14 Jun 2026 00:00:00 GMTdrugs-fdafentanylopioidsvaccinesaddictionpublic-healthdodMarcus Chenhttps://thefirstcohort.com/articles/2026-06-14-a-fentanyl-vaccine-for-mice-an-overdose-decline-for-humans/https://thefirstcohort.com/articles/2026-06-14-a-fentanyl-vaccine-for-mice-an-overdose-decline-for-humans/Scripps Research published a clever chemistry redesign that let mice's immune systems recognize an entire class of fentanyl analogues. The headlines called it an overdose blocker. The mice are doing fine. Humans are years away, and the overdose decline is already happening without it.Sun, 14 Jun 2026 00:00:00 GMTdrugs-fdafentanylvaccinesaddiction-treatmentscripps-researchoverdose-deathsLena Marshallhttps://thefirstcohort.com/articles/2026-06-14-brain-gains-into-your-90s-are-probably-real-the-index-measuring-them-has-a-paten/https://thefirstcohort.com/articles/2026-06-14-brain-gains-into-your-90s-are-probably-real-the-index-measuring-them-has-a-paten/A three-year UT Dallas study tracking nearly 4,000 adults to age 94 says brain function can climb at any age. The biology is plausible. The catch is that the people measuring the gain are the same people patenting the yardstick.Sun, 14 Jun 2026 00:00:00 GMTbrain-agingbrain-agingneuroplasticitycognitionbrain-traininglongevityconflicts-of-interestSarah Okonkwohttps://thefirstcohort.com/articles/2026-06-14-the-battlefield-medicine-revolution-was-built-on-fake-wounds/https://thefirstcohort.com/articles/2026-06-14-the-battlefield-medicine-revolution-was-built-on-fake-wounds/A British prosthetics graduate is heading to NHS ambulance crews and the British military to build realistic trauma wounds, the artisan end of the twenty-year battlefield-medicine revolution that turned hemorrhage into a survivable injury.Sun, 14 Jun 2026 00:00:00 GMTinfectious-diseasemilitary-medicinetrauma-caresimulationtcccpublic-health-readinessmoulageMarcus Chenhttps://thefirstcohort.com/articles/2026-06-14-your-thymus-quietly-stages-a-lung-researchers-just-named-the-cell-playing-the-pa/https://thefirstcohort.com/articles/2026-06-14-your-thymus-quietly-stages-a-lung-researchers-just-named-the-cell-playing-the-pa/A new Nature Immunology study identifies an alveolar lung-like cell hiding inside the thymus, where it appears to teach the immune system not to attack your real lungs.Sun, 14 Jun 2026 00:00:00 GMTautoimmune-inflammationthymusautoimmunitycentral-tolerancemteclung-autoimmunityimmunologySarah Okonkwohttps://thefirstcohort.com/articles/2026-06-13-a-korean-lab-found-cancer-s-dna-repair-off-switch-in-a-mouse/https://thefirstcohort.com/articles/2026-06-13-a-korean-lab-found-cancer-s-dna-repair-off-switch-in-a-mouse/A Korean state lab reports that a tool compound called UNI418 strips out the DNA-repair proteins cancer cells use to escape PARP inhibitors. The data are preclinical: cell lines and mouse xenografts. UNI418 is not yet a drug.Sat, 13 Jun 2026 00:00:00 GMTcancercancerparp-inhibitorsdna-repairpreclinicaldrug-resistanceLena Marshallhttps://thefirstcohort.com/articles/2026-06-13-a-near-starvation-diet-shifted-inflammation-in-gum-disease-patients-the-trial-wa/https://thefirstcohort.com/articles/2026-06-13-a-near-starvation-diet-shifted-inflammation-in-gum-disease-patients-the-trial-wa/A 28-patient feasibility trial put severe gum-disease patients on three cycles of a 750-calorie ProLon diet. Inflammation markers trended lower; clinical gum measures weren't reported. The biology question is real; the data is thin.Sat, 13 Jun 2026 00:00:00 GMTautoimmune-inflammationfastingperiodontitisinflammationpilot-trialprolonnutritionSarah Okonkwohttps://thefirstcohort.com/articles/2026-06-13-medicare-s-product-hopping-loophole-is-back-on-the-chopping-block-the-bigger-pha/https://thefirstcohort.com/articles/2026-06-13-medicare-s-product-hopping-loophole-is-back-on-the-chopping-block-the-bigger-pha/The Trump administration on Thursday proposed closing the product-hopping loophole that lets drugmakers reset Medicare's negotiation clock by tweaking inactive ingredients. It is the same fix the same administration quietly tabled in October.Sat, 13 Jun 2026 00:00:00 GMTdrugs-fdadrug-pricingmedicarepharmaglp-1product-hoppingregulatory-captureSarah Okonkwohttps://thefirstcohort.com/articles/2026-06-13-the-same-mutations-that-drive-blood-cancer-keep-turning-up-in-alzheimer-s-brains/https://thefirstcohort.com/articles/2026-06-13-the-same-mutations-that-drive-blood-cancer-keep-turning-up-in-alzheimer-s-brains/A new Cell paper finds Alzheimer's brains are riddled with the same mutations that drive blood cancers, in the immune cells that are supposed to be protecting neurons.Sat, 13 Jun 2026 00:00:00 GMTbrain-agingalzheimersmicrogliasomatic-mutationsneurodegenerationclonal-hematopoiesisamyloidSarah Okonkwohttps://thefirstcohort.com/articles/2026-06-10-8-300-brazilian-elders-one-saltshaker-and-the-80-percent-of-sodium-nobody-mentio/https://thefirstcohort.com/articles/2026-06-10-8-300-brazilian-elders-one-saltshaker-and-the-80-percent-of-sodium-nobody-mentio/A Frontiers in Public Health survey of 8,336 Brazilians over 60 found older men reach for the saltshaker most. Buried in the same paper: the shaker only accounts for 6 to 20 percent of total sodium. The other 70-plus percent already arrived from the factory.Wed, 10 Jun 2026 00:00:00 GMTnutrition-foodnutritionpublic-healthultra-processed-foodcognitive-declinesodiumSarah Okonkwohttps://thefirstcohort.com/articles/2026-06-10-american-doctors-get-about-1-2-hours-of-nutrition-training-a-year-rfk-jr-just-fo/https://thefirstcohort.com/articles/2026-06-10-american-doctors-get-about-1-2-hours-of-nutrition-training-a-year-rfk-jr-just-fo/Kennedy got eight organizations across U.S. medical training and 73 medical schools to commit to nutrition in licensing, accreditation, and a 40-hour pledge. The board exam matters; the rest is partly hedging.Wed, 10 Jun 2026 00:00:00 GMTnutrition-foodnutritionmedical-educationmaharfkusmlechronic-diseaseSarah Okonkwohttps://thefirstcohort.com/articles/2026-06-10-disappointment-not-reward-is-what-breaks-a-habit-half-of-older-adults-are-on-dru/https://thefirstcohort.com/articles/2026-06-10-disappointment-not-reward-is-what-breaks-a-habit-half-of-older-adults-are-on-dru/An OIST team caught the mouse brain firing acetylcholine the moment an expected reward failed to land. That surge is what lets the animal switch strategy. Close to half of community-dwelling older adults are on drugs that block the same receptors.Wed, 10 Jun 2026 00:00:00 GMTbrain-agingneurosciencebrain-chemistryhabitsanti-cholinergicsbehavioral-flexibilityaddictionSarah Okonkwohttps://thefirstcohort.com/articles/2026-06-10-europe-had-this-sunscreen-in-1999-the-fda-approved-it-tuesday/https://thefirstcohort.com/articles/2026-06-10-europe-had-this-sunscreen-in-1999-the-fda-approved-it-tuesday/A new chemical UV filter Europe approved in 1999 just cleared the FDA after a 21-year wait, while Americans relied on ingredients the agency's own 2019 review could not call safe.Wed, 10 Jun 2026 00:00:00 GMTdrugs-fdasunscreenfdaregulatory-captureskin-cancerwellnessphotoprotectionSarah Okonkwohttps://thefirstcohort.com/articles/2026-06-10-nitrate-from-spinach-behaves-nothing-like-nitrate-from-tap-water-a-27-year-cohor/https://thefirstcohort.com/articles/2026-06-10-nitrate-from-spinach-behaves-nothing-like-nitrate-from-tap-water-a-27-year-cohor/54,804 Danes followed for a quarter-century: less dementia from vegetable nitrate, more from drinking water. The risk signal shows up at roughly one-ninth of what the US EPA still permits.Wed, 10 Jun 2026 00:00:00 GMTbrain-agingnitratedementiadrinking-waterepan-nitrosaminesregulatory-captureSarah Okonkwohttps://thefirstcohort.com/articles/2026-06-10-the-ai-vaccine-that-passed-its-first-trial-three-years-ago/https://thefirstcohort.com/articles/2026-06-10-the-ai-vaccine-that-passed-its-first-trial-three-years-ago/Cambridge finished the Phase 1 trial in 2023. The press tour arrived in 2026. The paper, when you read it, said the immunogenicity was modest.Wed, 10 Jun 2026 00:00:00 GMTinfectious-diseasevaccinesai-drug-designcoronavirusclinical-trialspandemic-preparednessregulatory-captureLena Marshallhttps://thefirstcohort.com/articles/2026-06-09-altair-missed-its-primary-endpoint-the-press-tour-found-something-else/https://thefirstcohort.com/articles/2026-06-09-altair-missed-its-primary-endpoint-the-press-tour-found-something-else/A phase 3 trial testing chemotherapy in ctDNA-positive colorectal cancer patients missed its primary endpoint at p=0.107, and a post-hoc reanalysis is doing the public-facing work.Tue, 09 Jun 2026 00:00:00 GMTcancercolorectal-cancerctdnaclinical-trialsoncologypharma-skepticismLena Marshallhttps://thefirstcohort.com/articles/2026-06-09-fish-oil-rewired-the-t-cells-in-non-obese-diabetic-rats-and-the-glucose-moved-wi/https://thefirstcohort.com/articles/2026-06-09-fish-oil-rewired-the-t-cells-in-non-obese-diabetic-rats-and-the-glucose-moved-wi/A Brazilian team gave EPA-heavy fish oil to a non-obese diabetic rat strain for eight weeks. Glucose, insulin sensitivity, and lipids all moved in the friendlier direction. The T-cell balance shifted alongside them, and that is the part of the paper worth chewing on.Tue, 09 Jun 2026 00:00:00 GMTautoimmune-inflammationomega-3type-2-diabetesinsulin-resistanceinflammationpreclinicallipidsSarah Okonkwohttps://thefirstcohort.com/articles/2026-06-09-six-melanoma-patients-six-weeks-one-common-variable-the-question-oncology-is-cho/https://thefirstcohort.com/articles/2026-06-09-six-melanoma-patients-six-weeks-one-common-variable-the-question-oncology-is-cho/An oncologist's bedside pattern, a Senate hearing, and a mechanism paper sitting in a mainstream oncology journal: the case that repeated mRNA boosters may be lifting the brakes off cancers oncologists thought they had quiet is no longer fringe enough to wave away.Tue, 09 Jun 2026 00:00:00 GMTcancermrna-vaccinesoncologyimmune-tolerancemelanomaigg4regulatory-captureLena Marshallhttps://thefirstcohort.com/articles/2026-06-09-the-alzheimer-s-drug-that-bets-the-plaques-are-a-symptom/https://thefirstcohort.com/articles/2026-06-09-the-alzheimer-s-drug-that-bets-the-plaques-are-a-symptom/An ETH Zurich team spent nearly twenty years tracing why Alzheimer's nerve cells run out of energy, and the answer points to a protein the amyloid-clearing drugs never touched.Tue, 09 Jun 2026 00:00:00 GMTbrain-agingalzheimersneurosciencemitochondriadrug-developmentamyloid-hypothesiseth-zurichSarah Okonkwohttps://thefirstcohort.com/articles/2026-06-09-the-macaques-get-a-reprieve-pharma-gets-a-faster-pipeline/https://thefirstcohort.com/articles/2026-06-09-the-macaques-get-a-reprieve-pharma-gets-a-faster-pipeline/The FDA's new draft guidance lets oncology developers cut animal studies for certain biologics and conjugated products. The replacement laboratory methods are still being validated.Tue, 09 Jun 2026 00:00:00 GMTdrugs-fdafdaoncologyanimal-testingbiologicsantibody-drug-conjugatesregulatory-reformLena Marshallhttps://thefirstcohort.com/articles/2026-06-09-the-thin-trial-behind-england-s-next-supermarket-layout-mandate/https://thefirstcohort.com/articles/2026-06-09-the-thin-trial-behind-england-s-next-supermarket-layout-mandate/A non-randomized trial of 36 English discount stores produced a moment-of-implementation bump in produce sales that lost statistical significance by three months, and a household-purchasing signal that never landed. The authors' immediate call for a national layout mandate is the louder finding.Tue, 09 Jun 2026 00:00:00 GMTnutrition-foodpublic-healthnutritionukfood-policyregulationchoice-architectureMarcus Chenhttps://thefirstcohort.com/articles/2026-06-07-a-16-foot-fire-tornado-burned-an-oil-slick-with-40-less-soot-cleanup-crews-have/https://thefirstcohort.com/articles/2026-06-07-a-16-foot-fire-tornado-burned-an-oil-slick-with-40-less-soot-cleanup-crews-have/A federally funded field trial used a controlled fire whirl to burn up to 95% of a crude oil pool while cutting soot by 40%, raising the question of why the standard in-situ burn, with its measured worker-lung cost, has gone unchallenged for thirty-five years.Sun, 07 Jun 2026 00:00:00 GMTinvestigationsoil-spillfire-whirlenvironmental-healthparticulate-matterdeepwater-horizonSarah Okonkwohttps://thefirstcohort.com/articles/2026-06-07-a-16-month-old-died-at-an-arkansas-splash-pad-its-chlorinator-had-been-broken-fo/https://thefirstcohort.com/articles/2026-06-07-a-16-month-old-died-at-an-arkansas-splash-pad-its-chlorinator-had-been-broken-fo/A new global synthesis on free-living amoebae explains why a single bad month at a public splash pad is enough to kill a child, and why the CDC's existing protocol would have caught it.Sun, 07 Jun 2026 00:00:00 GMTinfectious-diseaseamoebaenaegleria-fowleriwater-safetypublic-healthinfrastructureMarcus Chenhttps://thefirstcohort.com/articles/2026-06-07-a-senate-subcommittee-just-put-the-covid-shot-cancer-question-on-the-record/https://thefirstcohort.com/articles/2026-06-07-a-senate-subcommittee-just-put-the-covid-shot-cancer-question-on-the-record/A Senate Homeland Security subcommittee took testimony on whether mRNA COVID shots can plausibly cause cancer, and on the parallel campaign to keep that question out of the journals. Dr. John Campbell walked his audience through it.Sun, 07 Jun 2026 00:00:00 GMTinvestigationscovid-vaccinesmrnasenate-hearingregulatory-capturecancerrfk-jrMarcus Chenhttps://thefirstcohort.com/articles/2026-06-07-he-shou-wu-s-hair-loss-pitch-is-better-than-i-expected-its-liver-record-is-worse/https://thefirstcohort.com/articles/2026-06-07-he-shou-wu-s-hair-loss-pitch-is-better-than-i-expected-its-liver-record-is-worse/Researchers at Guangdong Pharmaceutical University argue Polygonum multiflorum could become the next pattern-baldness lead. The follicle biology is interesting. The case series of acute liver failure on four continents are not.Sun, 07 Jun 2026 00:00:00 GMTnutrition-foodhair-losstraditional-chinese-medicinehepatotoxicitysupplement-safetydermatologypolygonum-multiflorumSarah Okonkwohttps://thefirstcohort.com/articles/2026-06-07-lilly-s-triple-agonist-hit-30-weight-loss-the-glucagon-bet-is-why/https://thefirstcohort.com/articles/2026-06-07-lilly-s-triple-agonist-hit-30-weight-loss-the-glucagon-bet-is-why/Lilly's triple agonist hit nearly 30% weight loss at 104 weeks at ADA 2026. The glucagon bet is what makes retatrutide different from semaglutide and Mounjaro, and it's what makes the open safety signals different too.Sun, 07 Jun 2026 00:00:00 GMTmetabolic-weightretatrutideobesitytype-2-diabetesglp-1eli-lillyada-2026Sarah Okonkwohttps://thefirstcohort.com/articles/2026-06-07-ozempic-s-30-percent-breast-cancer-headline-and-the-trial-evidence-it-walked-pas/https://thefirstcohort.com/articles/2026-06-07-ozempic-s-30-percent-breast-cancer-headline-and-the-trial-evidence-it-walked-pas/A single-system observational study at ASCO 2026 attached a roughly 30% lower breast-cancer rate to GLP-1 use. The randomized record already on the table is quieter.Sun, 07 Jun 2026 00:00:00 GMTcancerozempicglp-1breast-cancerasco-2026pharmaLena Marshallhttps://thefirstcohort.com/articles/2026-06-07-retatrutide-s-triple-receptor-triumph-came-with-a-one-in-five-skin-sensation-sig/https://thefirstcohort.com/articles/2026-06-07-retatrutide-s-triple-receptor-triumph-came-with-a-one-in-five-skin-sensation-sig/Eli Lilly's investigational retatrutide hit bariatric-surgery-level weight loss at ADA 2026. The highest-dose arm of TRIUMPH-4 also saw 20.9% of patients report abnormal skin sensations, and a small cardiac imbalance turned up in the type-2 trial. Both got far less stage time than the headline numbeSun, 07 Jun 2026 00:00:00 GMTmetabolic-weightglp-1obesityretatrutideeli-lillyada-2026drug-safetySarah Okonkwohttps://thefirstcohort.com/articles/2026-06-07-the-401-cbc-and-the-32-cbc-are-the-same-test/https://thefirstcohort.com/articles/2026-06-07-the-401-cbc-and-the-32-cbc-are-the-same-test/A Reddit pitch for a Quest reseller put receipts on a markup the insurance-billed lab market has spent years obscuring. A Florida cost study confirms what the consumer market already figured out.Sun, 07 Jun 2026 00:00:00 GMTinvestigationslab-testinghealthcare-pricingdirect-to-consumerquest-diagnosticsprice-transparencyLena Marshallhttps://thefirstcohort.com/articles/2026-06-07-the-herbal-steroid-that-hits-pharma-s-holy-grail-kidney-target/https://thefirstcohort.com/articles/2026-06-07-the-herbal-steroid-that-hits-pharma-s-holy-grail-kidney-target/A Shanghai lab reports a steroid from a Yunnan mountain plant, already sold over the counter to bodybuilders, suppresses the same kidney-fibrosis pathway Big Pharma keeps circling and never quite closes on.Sun, 07 Jun 2026 00:00:00 GMTautoimmune-inflammationkidneyfibrosislongevityherbaltgf-betaSarah Okonkwohttps://thefirstcohort.com/articles/2026-06-07-the-hernia-faq-that-forgets-to-mention-the-implant/https://thefirstcohort.com/articles/2026-06-07-the-hernia-faq-that-forgets-to-mention-the-implant/A polished hernia FAQ walks patients through recovery time, return-to-work, and lifestyle. It skips the question with 26,153 pending lawsuits behind it, and the no-mesh option the international guideline still keeps on the table.Sun, 07 Jun 2026 00:00:00 GMTinvestigationsherniasurgerymedical-devicesmeshchronic-painlitigationSarah Okonkwohttps://thefirstcohort.com/articles/2026-06-07-the-oral-glp-1-race-just-got-a-third-serious-contender-and-its-curve-was-still-c/https://thefirstcohort.com/articles/2026-06-07-the-oral-glp-1-race-just-got-a-third-serious-contender-and-its-curve-was-still-c/Structure Therapeutics' once-daily oral GLP-1 aleniglipron hit 11.3 percent placebo-adjusted weight loss at 36 weeks and kept climbing in the open label. The catch: oral semaglutide and orforglipron already cleared the FDA.Sun, 07 Jun 2026 00:00:00 GMTmetabolic-weightglp-1obesitymetabolicoral-medicationsstructure-therapeuticsphase-2bSarah Okonkwohttps://thefirstcohort.com/articles/2026-06-07-the-ozempic-resistance-headline-the-data-didn-t-quite-earn/https://thefirstcohort.com/articles/2026-06-07-the-ozempic-resistance-headline-the-data-didn-t-quite-earn/A new study identifies PAM-gene variants tied to weaker six-month HbA1c response to GLP-1 diabetes drugs, but the 'why Ozempic may not work' framing imports a weight-loss conclusion the paper doesn't reach, and the buried trials that used longer-acting GLP-1 drugs showed no carrier effect at all.Sun, 07 Jun 2026 00:00:00 GMTmetabolic-weightglp-1ozempicpharmacogenomicsnovo-nordiskdiabetesresearch-spinLena Marshallhttps://thefirstcohort.com/articles/2026-06-07-the-supplement-aisle-has-spent-twenty-years-getting-older-americans-wrong/https://thefirstcohort.com/articles/2026-06-07-the-supplement-aisle-has-spent-twenty-years-getting-older-americans-wrong/A May 2026 review by two geriatric researchers, syndicated this week by ScienceDaily, restates what twenty years of trial data have already shown: the supplement aisle is built around vague promises older Americans do not need, while protein, the gap that actually moves aging outcomes, sits in the mSun, 07 Jun 2026 00:00:00 GMTnutrition-foodsupplementsagingvitamin-dnutritionpublic-healthsarcopeniaMarcus Chenhttps://thefirstcohort.com/articles/2026-06-06-a-senate-hearing-finally-put-the-cancer-question-on-the-record-the-journal-notic/https://thefirstcohort.com/articles/2026-06-06-a-senate-hearing-finally-put-the-cancer-question-on-the-record-the-journal-notic/Sen. Ron Johnson's June 3 subcommittee hearing on plausible mechanisms linking mRNA injections to cancer, the South Korean cohort behind it, and the editorial notice Springer had posted on the paper months earlier.Sat, 06 Jun 2026 00:00:00 GMTinvestigationscovid-vaccinesmrnacancersenate-hearingretractionsron-johnsonLena Marshallhttps://thefirstcohort.com/articles/2026-06-06-cops-shoved-a-doctor-at-the-ada-meeting-the-editorial-they-tore-up-has-its-own-c/https://thefirstcohort.com/articles/2026-06-06-cops-shoved-a-doctor-at-the-ada-meeting-the-editorial-they-tore-up-has-its-own-c/Police escorted ADA members out of New Orleans on Friday for passing out an editorial against Trump's NIH overhaul. The shove was bad. The editorial defending the status quo has a credibility problem the press is mostly missing.Sat, 06 Jun 2026 00:00:00 GMTinvestigationsdiabetesnihmahapediatric-obesityresearch-fundingfree-speechSarah Okonkwohttps://thefirstcohort.com/articles/2026-06-06-pancreatic-cancer-s-undruggable-wall-just-cracked-the-follow-up-is-8-5-months-an/https://thefirstcohort.com/articles/2026-06-06-pancreatic-cancer-s-undruggable-wall-just-cracked-the-follow-up-is-8-5-months-an/Revolution Medicines' daraxonrasib nearly doubled median overall survival versus chemotherapy in previously treated metastatic pancreatic cancer at ASCO 2026, with 8.5 months of follow-up and a two-billion-dollar Royalty Pharma deal already riding on what comes next.Sat, 06 Jun 2026 00:00:00 GMTcancerpancreatic-cancerkrasfdaoncologydrug-pricingclinical-trialsLena Marshallhttps://thefirstcohort.com/articles/2026-06-06-the-founder-of-kentucky-s-biggest-rehab-chain-was-indicted-this-week-the-wire-fr/https://thefirstcohort.com/articles/2026-06-06-the-founder-of-kentucky-s-biggest-rehab-chain-was-indicted-this-week-the-wire-fr/A federal grand jury in the Eastern District of Kentucky indicted the founder of Addiction Recovery Care on June 4 for selling the same COVID-era tax credit twice. The bigger case, the FBI Medicaid investigation into the company he built, is still open.Sat, 06 Jun 2026 00:00:00 GMTinvestigationsmedicaid-fraudopioid-crisisregulatory-capturekentuckyfederal-indictmentpolitical-donationsMira Petrovhttps://thefirstcohort.com/articles/2026-06-04-a-gut-hormone-keeps-showing-up-in-the-brain-s-reward-circuit-and-600-000-veteran/https://thefirstcohort.com/articles/2026-06-04-a-gut-hormone-keeps-showing-up-in-the-brain-s-reward-circuit-and-600-000-veteran/A VA cohort of 606,000 diabetic veterans on GLP-1 drugs showed lower risks of new substance use disorders and large drops in overdose and drug-related death versus a peer diabetes drug. The mechanism story is where it gets interesting.Thu, 04 Jun 2026 00:00:00 GMTmetabolic-weightglp-1addictionneuroscienceveterans-healthpharmareward-circuitSarah Okonkwohttps://thefirstcohort.com/articles/2026-06-04-alnylam-bet-2-billion-on-ai-designed-rnai-the-check-it-actually-wrote-was-30-mil/https://thefirstcohort.com/articles/2026-06-04-alnylam-bet-2-billion-on-ai-designed-rnai-the-check-it-actually-wrote-was-30-mil/Alnylam paid Inceptive Nucleics $30 million up front, with up to $2 billion in milestones tied to outcomes the rest of AI drug discovery has spent a decade failing to deliver.Thu, 04 Jun 2026 00:00:00 GMTdrugs-fdarnaiai-drug-discoveryalnylambiotech-dealssirnapharmaMarcus Chenhttps://thefirstcohort.com/articles/2026-06-04-harvard-just-mapped-how-a-mouse-smells-and-it-quietly-rewrites-what-smell-loss-m/https://thefirstcohort.com/articles/2026-06-04-harvard-just-mapped-how-a-mouse-smells-and-it-quietly-rewrites-what-smell-loss-m/Harvard used MERFISH to image roughly 1,100 odorant receptors across the mouse nose at once and found tidy stripes, not chaos. The clinical stakes for smell loss just got harder to wave off.Thu, 04 Jun 2026 00:00:00 GMTbrain-agingolfactionneuroscienceanosmiasmell-lossparkinsonsharvardSarah Okonkwohttps://thefirstcohort.com/articles/2026-06-03-a-senior-niaid-scientist-got-caught-smuggling-113-vials-through-detroit-he-says/https://thefirstcohort.com/articles/2026-06-03-a-senior-niaid-scientist-got-caught-smuggling-113-vials-through-detroit-he-says/Two NIAID scientists are charged with bringing 113 undeclared vials into Detroit during an active Congo mpox outbreak. One allegedly told a federal officer he does it all the time.Wed, 03 Jun 2026 00:00:00 GMTinvestigationsnihniaidbiosafetympoxrocky-mountain-labspublic-trustMarcus Chenhttps://thefirstcohort.com/articles/2026-06-03-another-clot-problem-at-abiomed-the-fda-flags-an-impella-introducer-and-the-patt/https://thefirstcohort.com/articles/2026-06-03-another-clot-problem-at-abiomed-the-fda-flags-an-impella-introducer-and-the-patt/FDA flags Abiomed's 14Fr Low Profile Introducer Kit after a higher than expected complaint rate of clots forming on the device during prolonged Impella CP support. Three serious injuries reported, no deaths. The pattern keeps growing.Wed, 03 Jun 2026 00:00:00 GMTdrugs-fdafdaabiomedimpellamedical-devicesrecallcardiacSarah Okonkwohttps://thefirstcohort.com/articles/2026-06-03-half-a-billion-in-detainee-health-care-and-the-federal-watchdog-quietly-closed/https://thefirstcohort.com/articles/2026-06-03-half-a-billion-in-detainee-health-care-and-the-federal-watchdog-quietly-closed/A KFF and AP investigation pulled more than 300 sworn allegations of medical neglect from 33,000 ICE habeas petitions, even as the detention ombudsman office quietly closed and the federal detainee care bill passed half a billion dollars.Wed, 03 Jun 2026 00:00:00 GMTinvestigationsice-detentionprivate-contractorsmedical-neglectfederal-oversighthealthcare-spendingLena Marshallhttps://thefirstcohort.com/articles/2026-06-03-the-crunchy-mom-and-the-maha-mom-were-fighting-the-same-war-the-pesticide-lobby/https://thefirstcohort.com/articles/2026-06-03-the-crunchy-mom-and-the-maha-mom-were-fighting-the-same-war-the-pesticide-lobby/For one strange year, the EWG hiking-boots crowd and the MAHA red-hat moms were fighting the same pesticide war. Then Trump invoked the Defense Production Act on behalf of Bayer, the final MAHA report quietly stopped mentioning glyphosate, and a coalition that was actually winning got stomped by a CWed, 03 Jun 2026 00:00:00 GMTinvestigationsglyphosatepesticidesmahaenvironmental-healthrfk-jrfood-policySarah Okonkwohttps://thefirstcohort.com/articles/2026-06-03-the-fda-approved-a-better-penile-implant-for-most-men-ed-is-the-heart-warning-th/https://thefirstcohort.com/articles/2026-06-03-the-fda-approved-a-better-penile-implant-for-most-men-ed-is-the-heart-warning-th/The FDA approved Coloplast's Titan Prime inflatable penile prosthesis on June 3, 2026. For the men whose vasculature is past saving, it is a meaningful device upgrade. For most men with new ED, the more useful conversation is what the small arteries are failing to do years before the coronaries notiWed, 03 Jun 2026 00:00:00 GMTdrugs-fdaerectile-dysfunctionmens-healthcardiovascularmetabolicfdadevicesSarah Okonkwohttps://thefirstcohort.com/articles/2026-06-03-yale-s-olive-oil-cancer-story-did-not-actually-test-olive-oil/https://thefirstcohort.com/articles/2026-06-03-yale-s-olive-oil-cancer-story-did-not-actually-test-olive-oil/A Yale mouse study reported in Cancer Discovery is being sold as proof that olive oil fuels pancreatic cancer. The lab fed the mice purified oleic acid, the effect only showed up in males, and no one has tested it in a person.Wed, 03 Jun 2026 00:00:00 GMTnutrition-foodpancreatic-cancerferroptosisomega-3mediterranean-dietpreclinicalyaleLena Marshallhttps://thefirstcohort.com/articles/2026-06-02-andrew-huberman-s-peptide-masterclass-and-the-published-evidence/https://thefirstcohort.com/articles/2026-06-02-andrew-huberman-s-peptide-masterclass-and-the-published-evidence/Andrew Huberman's June 1 episode on peptides walks through BPC-157 and seven other compounds. The published human evidence for its lead substance runs to fewer than thirty people.Tue, 02 Jun 2026 00:00:00 GMTdrugs-fdapeptidesbpc-157hubermanfdamelanotanregulationLena Marshallhttps://thefirstcohort.com/articles/2026-06-02-fda-s-new-gene-therapy-shortcut-leans-on-platform-knowledge-six-months-ago-they/https://thefirstcohort.com/articles/2026-06-02-fda-s-new-gene-therapy-shortcut-leans-on-platform-knowledge-six-months-ago-they/FDA's new gene therapy draft guidance invites sponsors to lean on "platform knowledge" to streamline submissions, six months after the agency revoked Sarepta's AAVrh74 platform designation following three patient deaths.Tue, 02 Jun 2026 00:00:00 GMTdrugs-fdafdagene-therapyregulatory-capturerare-diseaseaccelerated-approvalgenome-editingSarah Okonkwohttps://thefirstcohort.com/articles/2026-06-02-six-negative-tests-forty-two-days-what-australia-s-biosecurity-order-won-t-say-o/https://thefirstcohort.com/articles/2026-06-02-six-negative-tests-forty-two-days-what-australia-s-biosecurity-order-won-t-say-o/Australia extended facility detention of six hantavirus contacts to a full 42 days under the Biosecurity Act after they tested negative. WHO's own guidance reserves that option for the high-risk tier; most peer countries chose monitoring.Tue, 02 Jun 2026 00:00:00 GMTinvestigationsbiosecurity-actquarantinehantavirusaustraliapublic-healthcivil-libertiesMira Petrovhttps://thefirstcohort.com/articles/2026-06-02-xocova-clears-the-fda-what-it-actually-prevents-is-the-smaller-story/https://thefirstcohort.com/articles/2026-06-02-xocova-clears-the-fda-what-it-actually-prevents-is-the-smaller-story/The FDA approved Shionogi's ensitrelvir for post-exposure COVID prevention, citing a 67% relative risk reduction. Look at what the trial actually measured and a different story comes into focus.Tue, 02 Jun 2026 00:00:00 GMTinfectious-diseasecovid-19antiviralsfdapost-exposure-prophylaxisshionogiMarcus Chenhttps://thefirstcohort.com/articles/2026-05-30-hepatitis-delta-has-waited-forty-nine-years-for-a-drug-the-fda-made-american-pat/https://thefirstcohort.com/articles/2026-05-30-hepatitis-delta-has-waited-forty-nine-years-for-a-drug-the-fda-made-american-pat/The FDA cleared bulevirtide for chronic hepatitis delta this week, six years after Europe started using it and three years after a U.S. application was turned down on manufacturing grounds. The wait is its own story.Sat, 30 May 2026 00:00:00 GMTdrugs-fdahepatitisfdagileadregulatory-delayviral-hepatitisaccelerated-approvalMarcus Chenhttps://thefirstcohort.com/articles/2026-05-29-america-s-ebola-fortress-history-has-tested-this-strategy-and-it-failed/https://thefirstcohort.com/articles/2026-05-29-america-s-ebola-fortress-history-has-tested-this-strategy-and-it-failed/Washington has built a wall around the Ebola outbreak in Central Africa. The last time America tried this, the evidence says the wall leaked, and so did the response.Fri, 29 May 2026 00:00:00 GMTinfectious-diseaseebolapublic-healthbiosecurityinfectious-diseaseregulatory-failureMarcus Chenhttps://thefirstcohort.com/articles/2026-05-29-doctor-mike-plays-never-have-i-ever-with-a-firefighter-watch-what-s-around-the-b/https://thefirstcohort.com/articles/2026-05-29-doctor-mike-plays-never-have-i-ever-with-a-firefighter-watch-what-s-around-the-b/Doctor Mike's lighthearted Never Have I Ever video sits at the top of a funnel that includes a $997 media academy, a UNICEF vaccine-ambassador title, and an ongoing pitch to pharmaceutical executives about social-media trust.Fri, 29 May 2026 00:00:00 GMTinvestigationsmediainfluencer-medicinepharma-marketingpublic-trustvaccinesdoctor-mikeMarcus Chenhttps://thefirstcohort.com/articles/2026-05-29-vietnam-s-new-integrity-rule-arrives-251-retractions-late/https://thefirstcohort.com/articles/2026-05-29-vietnam-s-new-integrity-rule-arrives-251-retractions-late/Vietnam's Ministry of Science and Technology issued a research-integrity framework with permanent bans on May 25, 2026. The Retraction Watch database already lists 251 retractions carrying Vietnamese affiliations.Fri, 29 May 2026 00:00:00 GMTinvestigationsresearch-integrityvietnampaper-millsretractionsaccountabilityregulationMira Petrov